AzurRx BioPharma Inc. (NASDAQ:AZRX) has a beta value of 1.5 and has seen 1,046,440 shares traded in the last trading session. The company, currently valued at $68.11 Million, closed the last trade at $0.91 per share which meant it lost -$0.04 on the day or -4.09% during that session. The AZRX stock price is -189.01% off its 52-week high price of $2.63 and 39.23% above the 52-week low of $0.553. If we look at the company’s 10-day average daily trading volume, we find that it stood at 9.38 Million shares traded. The 3-month trading volume is 9.93 Million shares.
The consensus among analysts is that AzurRx BioPharma Inc. (AZRX) is an Overweight stock at the moment, with a recommendation rating of 2.2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 4 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.07.
AzurRx BioPharma Inc. (NASDAQ:AZRX) trade information
Despite being -4.09% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Apr 27 when the AZRX stock price touched $1.0699 or saw a rise of 14.49%. Year-to-date, AzurRx BioPharma Inc. shares have moved -5.68%, while the 5-day performance has seen it change 8.37%. Over the past 30 days, the shares of AzurRx BioPharma Inc. (NASDAQ:AZRX) have changed -29.62%. Short interest in the company has seen 1.83 Million shares shorted with days to cover at 0.18.
Wall Street analysts have a consensus price target for the stock at $3.5, which means that the shares’ value could jump 284.62% from current levels. The projected low price target is $2.5 while the price target rests at a high of $5. In that case, then, we find that the current price level is +449.45% off the targeted high while a plunge would see the stock lose 174.73% from current levels.
AzurRx BioPharma Inc. (AZRX) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -19% over the past 5 years. Earnings growth for 2021 is a modest -116.8%.
AzurRx BioPharma Inc. (NASDAQ:AZRX)’s Major holders
Insiders own 1.03% of the company shares, while shares held by institutions stand at 2.61% with a share float percentage of 2.64%. Investors are also buoyed by the number of investors in a company, with AzurRx BioPharma Inc. having a total of 19 institutions that hold shares in the company. The top two institutional holders are Vanguard Group Inc. (The) with over 685.92 Thousand shares worth more than $665.34 Thousand. As of December 30, 2020, Vanguard Group Inc. (The) held 0.92% of shares outstanding.
The other major institutional holder is Bank Of New York Mellon Corporation, with the holding of over 430.84 Thousand shares as of December 30, 2020. The firm’s total holdings are worth over $417.91 Thousand and represent 0.58% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of December 30, 2020, the former fund manager holds about 0.66% shares in the company for having 490181 shares of worth $475.48 Thousand while later fund manager owns 185.72 Thousand shares of worth $180.14 Thousand as of December 30, 2020, which makes it owner of about 0.25% of company’s outstanding stock.